Research in Progress (RIP): "Screening for Breast Cancer: New Guidelines, Old Controversies"
Please note: All research in progress seminars are off-the-record. Any information about methodology and/or results are embargoed until publication.
Summary
In this talk I’ll provide a history of the breast cancer screening controversies and discuss the new guidelines from the US Preventive Services Task Force and the American Cancer Society.
Douglas K. Owens
Encina Commons, Room 201
615 Crothers Way Stanford, CA 94305-6006
Executive Assistant: Soomin Li, soominli@stanford.edu
Phone: (650) 725-9911
Douglas K. Owens is the Henry J. Kaiser, Jr. Professor, Chair of the Department of Health Policy in the Stanford University School of Medicine and Director of the Center for Health Policy (CHP) in the Freeman Spogli Institute for International Studies (FSI). He is a general internist, a Professor of Management Science and Engineering (by courtesy), at Stanford University; and a Senior Fellow at the Freeman Spogli Institute for International Studies.
Owens' research includes the application of decision theory to clinical and health policy problems; clinical decision making; methods for developing clinical guidelines; decision support; comparative effectiveness; modeling substance use and infectious diseases; cardiovascular disease; patient-centered decision making; assessing the value of health care services, including cost-effectiveness analysis; quality of care; and evidence synthesis.
Owens chaired the Clinical Guidelines Committee of the American College of Physicians for four years. The guideline committee develops clinical guidelines that are used widely and are published regularly in the Annals of Internal Medicine. He was a member and then Vice-Chair and Chair of the U.S. Preventive Services Task Force, which develops national guidelines on preventive care, including guidelines for screening for breast, colorectal, prostate, and lung cancer. He has helped lead the development of more than 50 national guidelines on treatment and prevention. He also was a member of the Second Panel on Cost Effectiveness in Health and Medicine, which developed guidelines for the conduct of cost-effectiveness analyses.
Owens also directed the Stanford-UCSF Evidence-based Practice Center. He co-directs the Stanford Health Services Research Program, and previously directed the VA Physician Fellowship in Health Services Research, and the VA Postdoctoral Informatics Fellowship Program.
Owens received a BS and an MS from Stanford University, and an MD from the University of California-San Francisco. He completed a residency in internal medicine at the University of Pennsylvania and a fellowship in health research and policy at Stanford. Owens is a past-President of the Society for Medical Decision Making. He received the VA Undersecretary’s Award for Outstanding Achievement in Health Services Research, and the Eisenberg Award for Leadership in Medical Decision Making from the Society for Medical Decision Making. Owens also received a MERIT award from the National Institutes on Drug Abuse to study HIV, HCV, and the opioid epidemic. He was elected to the American Society for Clinical Investigation (ASCI) and the Association of American Physicians (AAP.)
In March 2015, the first biosimilar product was approved in the U.S. as per the Biologics Price Competition and Innovation Act (BPCI Act) of 2009, section 351(k) biologics license application (BLA). Five years after the enactment of the BPCI Act and following its first biosimilar approval, the U.S. Food and Drug Administration (U.S. FDA) finalized its initial guidance describing the scientific and regulatory expectations for biosimilar approval under the 351 (k) pathway. Biologic manufacturers are provided with regulatory guidance in the form of scientific considerations, quality considerations and questions & answers regarding the implementation of the BPCI Act. With this new regulation, many BLA applications are under review by the U.S. FDA.
According to the National Tax Bureau in Japan, there were over three million Japanese family businesses in 2013. Additionally, companies in Japan are more sustainable than companies in the U.S. However, U.S. companies continue to find ways to be innovative. In her research, Takahashi attempts to answer the following questions – What is needed for sustainable management in the case of U.S-family businesses? and How have U.S. family businesses overcome external circumstances to become successful? Takahashi took over her family’s driving school business from her father in 2009. Based on her experiences owning a family business in Japan, she explored the successes and failures of family-owned businesses and how innovation of family business can sustain longevity in the U.S. Takahashi believes the conditions of management in Japan are rapidly changing, making companies unable to keep up with effective management. As a result, Takahashi offers suggestions to Japanese family businesses to help improve sustainable management in Japan.
The IT industry is producing many new types of internet-connected devices for consumers, including wearable devices, such as glasses and watches. Such devices may be more convenient than traditional devices because they are small and wearable and thus, literally always at hand. Every day, we receive many notifications on these devices making them very important connecting points for the media. Publishers prefer to distribute short texts for notifications, but this is not easily done. Because there are so many different types of devices available and no unified screen size, publishers cannot decide on the best format and length for these notifications. In his research, Tamori discusses suitable formats for notifications on small devices. By using a natural language processing method for automatic text summarization, Tamori developed an application that produces various formats of notifications for news depending on the display size. He also evaluated which form is best for small devices.